BOLT BIOTHERAPEUTICS
NASDAQ: BOLT (Bolt Biotherapeutics, Inc.)
最近更新时间: 13小时之前6.59
0.23 (3.62%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Bolt Biotherapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | 1.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 相对估值 | NA |
| 财务健康 | -0.5 |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.54 |
|
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.26% |
| 机构持股比例 | 46.17% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Board Of Trustees Of The Leland Stanford Junior University | 30 Jun 2026 | 35,977 |
| Pfizer Inc | 30 Jun 2026 | 31,305 |
| Lynx1 Capital Management Lp | 30 Jun 2026 | 30,800 |
| Nan Fung Group Holdings Ltd | 30 Jun 2026 | 5,000 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| GUJRATHI SHEILA | 6.27 | - | 85,821 | 538,098 |
| 累积净数量 | 85,821 | |||
| 累积净值 ($) | 538,098 | |||
| 累积平均购买 ($) | 6.27 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| GUJRATHI SHEILA | 职员 | 23 Oct 2026 | 获得 (+) | 72,766 | 6.27 | 456,243 |
| GUJRATHI SHEILA | 职员 | 23 Oct 2026 | 获得 (+) | 13,055 | 6.27 | 81,855 |
投资组合